Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy

Proceedings of the Japan Academy Series B: Physical and Biological Sciences

Volumn 91, Issue 7, 2015, Pages 292-304

  Taniguchi, Masaru ^a   Harada, Michishige ^a   Dashtsoodol, Nyambayar ^a   Kojo, Satoshi ^a  

^a RIKEN Center for Integrative Medical Sciences   (Japan)

Author keywords

Adjuvant effects; Induced pluripotent stem cells; NKT cell targeted therapy; NKT cells; galactosylceramide

Indexed keywords

IPS; MUS;

AMINO ACID SEQUENCE; ANIMAL; CLINICAL TRIAL (TOPIC); CYTOLOGY; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MOLECULAR EVOLUTION; NATURAL KILLER T CELL; NEOPLASMS; PROCEDURES;

AMINO ACID SEQUENCE; ANIMALS; CLINICAL TRIALS AS TOPIC; EVOLUTION, MOLECULAR; HUMANS; IMMUNOTHERAPY; INDUCED PLURIPOTENT STEM CELLS; NATURAL KILLER T-CELLS; NEOPLASMS;

EID: 84937419087     PISSN: 03862208     EISSN: 13492896     Source Type: Journal    
DOI: 10.2183/pjab.91.292     Document Type: Review

References (48)

1. Taniguchi, M., Harada, M., Kojo, S., Nakayama, T. and Wakao, H. (2003) The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21, 483-513.
2. Godfrey, D.I., MacDonald, H.R., Kronenberg, M., Smyth, M.J. and Van Kaer, L. (2004) NKT cells:what's in a name? Nat. Rev. Immunol. 4, 231-237.
3. Bendelac, A., Savage, P.B. and Teyton, L. (2007) The biology of NKT cells. Annu. Rev. Immunol. 25, 297-336.
4. Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M. and Taniguchi, M. (1997) Requirement for V,14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626.
5. Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., Koseki, H. and Taniguchi, M. (1997) CD1d-restricted and TCR-mediated activation of V,14 NKT cells by glycosylceramides. Science 278, 1626-1629.
6. Imai, K., Kanno, M., Kimoto, H., Shigemoto, K., Yamamoto, S. and Taniguchi, M. (1986) Sequence and expression of transcripts of the T-cell antigen receptor ,αchain gene in a functional, antigenspecific suppressor-T-cell hybridoma. Proc. Natl. Acad. Sci. U.S.A. 83, 8708-8712.
7. Koseki, H., Imai, K., Ichikawa, T., Hayata, I. and Taniguchi, M. (1989) Predominant use of a particular ,αchain in suppressor T cell hybridomas specific for keyhole limpet hemocyanin. Int. Immunol. 1, 557-564.
8. + T-cell antigen receptor , chain expanded in unprimed mice. Proc. Natl. Acad. Sci. U.S.A. 87, 5248-5252.
9. Kanno, R., Mizutani, Y., Saitou, N., Koseki, H., Makino, M., Adachi, Y., Akasaka, T., Kanno, M., Shiroishi, T., Moriwaki, K. and Taniguchi, M. (1994) Evolution of V,14 TCR gene family in mice. In Genetics in Wild Mice (eds. Moriwaki, K., Shiroishi, T. and Yonekawa, H.). Japan Scientific Societies Press, Karger, Tokyo, Basel, pp. 193-202.
10. Koseki, H., Imai, K., Nakayama, F., Sado, T., Moriwaki, K. and Taniguchi, M. (2014) Pillars article: homogenous junctional sequence of the V14D T-cell antigen receptor alpha chain expanded in unprimed m. Proc. Natl. Acad. Sci. U.S.A. 1990. 87: 5248-5252. J. Immunol. 193, 993-997.
11. + subset. J. Immunol. 145, 1039-1045.
12. + cells. J. Immunol. 145, 3209-3215.
13. Arase, H., Arase, N., Nakagawa, K., Good, R.A. and Onoe, K. (1993) NK1.1+ CD4D CD8- thymocytes with specific lymphokine secretion. Eur. J. Immunol. 23, 307-310.
14. - T cells in mice and humans. J. Exp. Med. 180, 1097-1106.
15. Yoshimoto, T. and Paul, W.E. (1994) CD+pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179, 1285-1295.
16. Sato, H., Nakayama, T., Tanaka, Y., Yamashita, M., Shibata, Y., Kondo, E., Saito, Y. and Taniguchi, M. (1999) Induction of differentiation of pre-NKT cells to mature V,14 NKT cells by granulocyte/ macrophage colony-stimulating factor. Proc. Natl. Acad. Sci. U.S.A. 96, 7439-7444.
17. Makino, Y., Kanno, R., Koseki, H. and Taniguchi, M. (1996) Development of V,14D NK T cells in the early stages of embryogenesis. Proc. Natl. Acad. Sci. U.S.A. 93, 6516-6520.
18. Kimura, M. (1983) Evolution of Genes and Proteins (eds. Nei, M. and Koehn, R.K.). Sinauer Associates, Inc., Sunderland Massachusetts, pp. 208-233.
19. Lu, B.Z. and Nei, M. (1989) Study on molecular evolution for both variable segments of immunoglobulin heavy chain and T cell receptor. Acta Genet. Sin. 16, 140-150.
20. Adachi, Y., Koseki, H., Zijlstra, M. and Taniguchi, M. (1995) Positive selection of invariant V alpha 14D T cells by non-major histocompatibility complex-encoded class I-like molecules expressed on bone marrow-derived cells. Proc. Natl. Acad. Sci. U.S.A. 92, 1200-1204.
21. Zeng, Z., Castano, A.R., Segelke, B.W., Stura, E.A., Peterson, P.A. and Wilson, I.A. (1997) Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove. Science 277, 339-345.
22. Kamada, N., Iijima, H., Kimura, K., Harada, M., Shimizu, E., Motohashi, S., Kawano, T., Shinkai, H., Nakayama, T., Sakai, T., Brossay, L., Kronenberg, M. and Taniguchi, M. (2001) Crucial amino acid residues of mouse CD1d for glycolipid ligand presentation to V,14 NKT cells. Int. Immunol. 13, 853-861.
23. Borg, N.A., Wun, K.S., Kjer-Nielsen, L., Wilce, M.C., Pellicci, D.G., Koh, R., Besra, G.S., Bharadwaj, M., Godfrey, D.I., McCluskey, J. and Rossjohn, J. (2007) CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448, 44-49.
24. Reinherz, E.L., Tan, K., Tang, L., Kern, P., Liu, J., Xiong, Y., Hussey, R.E., Smolyar, A., Hare, B., Zhang, R., Joachimiak, A., Chang, H.C., Wagner, G. and Wang, J. (1999) The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286, 1913-1921.
25. Brossay, L., Chioda, M., Burdin, N., Koezuka, Y., Casorati, G., Dellabona, P. and Kronenberg, M. (1998) CD1d-mediated recognition of an alphagalactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188, 1521-1528.
26. Spada, F.M., Koezuka, Y. and Porcelli, S.A. (1998) CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188, 1529-1534.
27. Burdin, N., Brossay, L., Degano, M., Iijima, H., Gui, M., Wilson, I.A. and Kronenberg, M. (2000) Structural requirements for antigen presentation by mouse CD1. Proc. Natl. Acad. Sci. U.S.A. 97, 10156-10161.
28. Brigl, M. and Brenner, M.B. (2004) CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22, 817-890.
29. Taniguchi, M., Seino, K. and Nakayama, T. (2003) The NKT cell system: bridging innate and acquired immunity. Nat. Immunol. 4, 1164-1165.
30. Fujii, S., Shimizu, K., Hemmi, H., Fukui, M., Bonito, A.J., Chen, G., Franck, R.W., Tsuji, M. and Steinman, R.M. (2006) Glycolipid ,αC-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc. Natl. Acad. Sci. U.S.A. 103, 11252-11257.
31. Lippitz, B.E. (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 14, e218-e228.
32. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L. and Steinman, R.M. (2003) Activation of natural killer T cells by ,αgalactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD+ and CD8T cell immunity to a coadministered protein. J. Exp. Med. 198, 267-279.
33. Fujii, S., Liu, K., Smith, C., Bonito, A.J. and Steinman, R.M. (2004) The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199, 1607-1618.
34. Toura, I., Kawano, T., Akutsu, Y., Nakayama, T., Ochiai, T. and Taniguchi, M. (1999) Cutting edge:inhibition of experimental tumor metastasis by dendritic cells pulsed with ,αgalactosylceramide. J. Immunol. 163, 2387-2391.
35. Ishikawa, A., Motohashi, S., Ishikawa, E., Fuchida, H., Higashino, K., Otsuji, M., Iizasa, T., Nakayama, T., Taniguchi, M. and Fujisawa, T. (2005) A phase I study of ,αgalactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11, 1910-1917.
36. Motohashi, S., Ishikawa, A., Ishikawa, E., Otsuji, M., Iizasa, T., Hanaoka, H., Shimizu, N., Horiguchi, S., Okamoto, Y., Fujii, S., Taniguchi, M., Fujisawa, T. and Nakayama, T. (2006) A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 12, 6079-6086.
37. Ishikawa, E., Motohashi, S., Ishikawa, A., Ito, T., Uchida, T., Kaneko, T., Tanaka, Y., Horiguchi, S., Okamoto, Y., Fujisawa, T., Tsuboi, K., Taniguchi, M., Matsumura, A. and Nakayama, T. (2005) Dendritic cell maturation by CD11c! T cells and V,24D natural killer T-cell activation by ,- galactosylceramide. Int. J. Cancer 117, 265-273.
38. Motohashi, S., Nagato, K., Kunii, N., Yamamoto, H., Yamasaki, K., Okita, K., Hanaoka, H., Shimizu, N., Suzuki, M., Yoshino, I., Taniguchi, M., Fujisawa, T. and Nakayama, T. (2009) A phase I-II study of ,αgalactosylceramide-pulsed IL-2/GM-CSFcultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J. Immunol. 182, 2492-2501.
39. Nagato, K., Motohashi, S., Ishibashi, F., Okita, K., Yamasaki, K., Moriya, Y., Hoshino, H., Yoshida, S., Hanaoka, H., Fujii, S., Taniguchi, M., Yoshino, I. and Nakayama, T. (2012) Accumulation of activated invariant natural killer T cells in the tumor microenvironment after alphaαgalactosylceramide- pulsed antigen presenting cells. J. Clin. Immunol. 32, 1071-1081.
40. Mountain, C.F. (1997) Revisions in the International System for Staging Lung Cancer. Chest 111, 1710-1717.
41. Huisman, C., Smit, E.F., Giaccone, G. and Postmus, P.E. (2000) Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J. Clin. Oncol. 18, 3722-3730.
42. Shepherd, F.A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., Coughlin, S., Kim, Y. and Berille, J. (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18, 2095-2103.
43. Socinski, M.A. (2003) The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. Respir. Care Clin. N. Am. 9, 207-236.
44. Yamasaki, K., Horiguchi, S., Kurosaki, M., Kunii, N., Nagato, K., Hanaoka, H., Shimizu, N., Ueno, N., Yamamoto, S., Taniguchi, M., Motohashi, S., Nakayama, T. and Okamoto, Y. (2011) Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin. Immunol. 138, 255-265.
45. Takahashi, K. and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676.
46. Watarai, H., Rybouchkin, A., Hongo, N., Nagata, Y., Sakata, S., Sekine, E., Dashtsoodol, N., Tashiro, T., Fujii, S., Shimizu, K., Mori, K., Masuda, K., Kawamoto, H., Koseki, H. and Taniguchi, M. (2010) Generation of functional NKT cells in vitro from embryonic stem cells bearing rearranged invariant Vα14-Jα18 TCRα gene. Blood 115, 230-237.
47. Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K. and Yamanaka, S. (2009) Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460, 1132-1135.
48. Watarai, H., Fujii, S., Yamada, D., Rybouchkin, A., Sakata, S., Nagata, Y., Iida-Kobayashi, M., Sekine-Kondo, E., Shimizu, K., Shozaki, Y., Sharif, J., Matsuda, M., Mochiduki, S., Hasegawa, T., Kitahara, G., Endo, T.A., Toyoda, T., Ohara, O., Harigaya, K., Koseki, H. and Taniguchi, M. (2010) Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells. J. Clin. Invest. 120, 2610-2618.